Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sacituzumab Tirumotecan (MK-2870) Monotherapy in Patients With Advanced or Metastatic Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-Based Combination Therapy: A Multicenter, Phase II Investigator-Initiated Registration-directed Trial (METROPOLIS；NCCH2503/MK018)

NCT07720258 is registered in ClinicalTrials.gov with National Cancer Center, Japan as lead sponsor.

NCT NCT07720258
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07720258 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sacituzumab Tirumotecan (MK-2870) Monotherapy in Patients With Advanced or Metastatic Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-Based Combination Therapy: A Multicenter, Phase II Investigator-Initiated Registration-directed Trial (METROPOLIS；NCCH2503/MK018)
Lead sponsor
National Cancer Center, Japan
Phase
Phase 2
Overall status
Not yet recruiting
Start date
January 1, 2027
Completion date
December 31, 2029
Enrollment
27 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced small bowel adenocarcinoma